Prescription drug plan (PDP): This is a stand-alone Medicare drug plan
In the treatment-policy estimand analysis, at week 26 oral semaglutide (1.2% mean A1C reduction from baseline) met criteria for noninferiority when compared with liraglutide (1.1% mean A1C reduction from baseline) and met criteria for superiority when compared with placebo (0.2% mean A1C reduction from baseline
[13] See also [edit] References [edit] 1 2 3 4 5 "Carnitine transport and fatty acid oxidation"
While generally safe, some individuals may experience mild side effects such as gastrointestinal discomfort or allergic reactions
Semaglutide also inhibits the liver's production of glucagon, a hormone that causes blood sugar levels to rise
Wang IK, Yen TH, Hsieh PS, Ho HH, Kuo YW, Huang YY, Kuo YL, Li CY, Lin HC, Wang JY